Loading
A phase 1/2 trial of Darolutamide in prostate cancer, run by Pathos AI, Inc., now recruiting.
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC is a phase 1/2 interventional study registered as NCT06785636 by Pathos AI, Inc., with 120 participants planned, started 2025-02-07 and due to reach its primary completion in 2028-06-30. Interventions recorded: Pocenbrodib, Pocenbrodib and Darolutamide. Conditions listed: mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors.
Shares Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/